» Articles » PMID: 32928757

Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study

Overview
Journal Ann Fam Med
Specialty Public Health
Date 2020 Sep 15
PMID 32928757
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Access to family planning health services in Canada has been historically inadequate and inequitable. A potential solution appeared when Health Canada approved mifepristone, the gold standard for medical abortion, in July 2015. We sought to investigate the factors that influence successful initiation and ongoing provision of medical abortion services among Canadian health professionals and how these factors relate to abortion policies, systems, and service access throughout Canada.

Methods: We conducted 1-on-1 semistructured interviews with a national sample of abortion-providing and nonproviding physicians and health system stakeholders in Canadian health care settings. Our data collection, thematic analysis, and interpretation were guided by Diffusion of Innovation theory.

Results: We conducted interviews with 90 participants including rural practitioners and those with no previous abortion experience. In the course of our study, Health Canada removed mifepristone restrictions. Our results suggest that Health Canada's initial restrictions discouraged physicians from providing mifepristone and were inconsistent with provincial licensing standards, thereby limiting patient access. Once deregulated, remaining factors were primarily related to local and regional implementation processes. Participants held strong perceptions that mifepristone was the new standard of care for medical abortion in Canada and within the scope of primary care practice.

Conclusion: Health Canada's removal of mifepristone restrictions facilitated the implementation of abortion care in the primary care setting. Our results are unique because Canada is the first country to facilitate provision of medical abortion in primary care via evidence-based deregulation of mifepristone.

Citing Articles

The role of doulas in abortion care in Canada: A qualitative study.

Paynter M, Heggie C, McLeod A, Castonguay M, Fuller M, Norman W PLoS One. 2025; 20(3):e0313918.

PMID: 40029891 PMC: 11875338. DOI: 10.1371/journal.pone.0313918.


A Health Professional Mentorship Platform to Improve Equitable Access to Abortion: Development, Usability, and Content Evaluation.

Abdulai A, Duong C, Stroulia E, Czerniak E, Chiu R, Mehta A JMIR Hum Factors. 2025; 12:e63364.

PMID: 39969819 PMC: 11864088. DOI: 10.2196/63364.


How integrated knowledge translation worked to reduce federal policy barriers to the implementation of medication abortion in Canada: a realist evaluation.

Munro S, Wahl K, Dunn S, Devane C, Li L, Norman W Implement Sci Commun. 2025; 6(1):16.

PMID: 39901300 PMC: 11792738. DOI: 10.1186/s43058-025-00694-0.


Primary Care Clinicians' Interest In, and Barriers To, Medication Abortion.

Neufeld L, Mark K J Am Board Fam Med. 2024; 37(4):680-689.

PMID: 39455277 PMC: 11781351. DOI: 10.3122/jabfm.2024.240005R1.


User-Centered Development of a Patient Decision Aid for Choice of Early Abortion Method: Multi-Cycle Mixed Methods Study.

Wahl K, Brooks M, Trenaman L, Desjardins-Lorimer K, Bell C, Chokmorova N J Med Internet Res. 2024; 26:e48793.

PMID: 38625731 PMC: 11061794. DOI: 10.2196/48793.


References
1.
Raymond E, Shannon C, Weaver M, Winikoff B . First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. Contraception. 2012; 87(1):26-37. DOI: 10.1016/j.contraception.2012.06.011. View

2.
Raymond E, Grimes D . The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol. 2012; 119(2 Pt 1):215-9. DOI: 10.1097/AOG.0b013e31823fe923. View

3.
Black A, Guilbert E, Costescu D, Dunn S, Fisher W, Kives S . Canadian Contraception Consensus (Part 1 of 4). J Obstet Gynaecol Can. 2015; 37(10):936-42. DOI: 10.1016/s1701-2163(16)30033-0. View

4.
Dawson A, Nicolls R, Bateson D, Doab A, Estoesta J, Brassil A . Medical termination of pregnancy in general practice in Australia: a descriptive-interpretive qualitative study. Reprod Health. 2017; 14(1):39. PMC: 5348908. DOI: 10.1186/s12978-017-0303-8. View

5.
Warden S, Genkin I, Hum S, Dunn S . Outcomes During Early Implementation of Mifepristone-Buccal Misoprostol Abortions up to 63 Days of Gestation in a Canadian Clinical Setting. J Obstet Gynaecol Can. 2019; 41(5):647-652. DOI: 10.1016/j.jogc.2018.05.030. View